

TABLE OF CONTENTS

0. Executive Summary	19
1. Introduction	21
Definitions	21
Historical evolution of gene therapy	21
Relation of gene therapy to other biotechnologies.....	23
Molecular biological basics for gene therapy.....	23
Genome.....	23
DNA	24
RNA	24
<i>Alternative RNA splicing</i>	<i>25</i>
Genes.....	26
Gene regulation	26
Gene expression	28
Chromosomes	28
Telomeres.....	29
Mitochondrial DNA.....	29
Proteins	30
2. Gene Therapy Technologies	31
Classification of gene therapy techniques	31
Ex vivo and in vivo gene therapy	32
Ex vivo gene therapy.....	32
In vivo gene therapy	33
Physical methods of gene transfer.....	33
Electroporation	33
Applications of electroporation	34
<i>Clinical applications of electroporation</i>	<i>35</i>
<i>Advantages of electroporation</i>	<i>35</i>
<i>Limitations of electroporation</i>	<i>36</i>
Hydrodynamic	36
Microinjection	36
Particle bombardment	37
Ultrasound-mediated transfection	39
Molecular vibration	40
Application of pulsed magnetic field and superparamagnetic nanoparticles	40
Gene transfection using laser irradiation	40
Photochemical transfection.....	41
Chemical methods of gene transfer.....	41
Gene repair and replacement.....	41
Gene repair by single-stranded oligonucleotides.....	42
History and current status of chimeraplasty.....	42
mRNA gene therapy	42
Spliceosome mediated RNA trans-splicing	43
Vectors for gene therapy	44
Basic considerations	44
Use of genes as pharmaceuticals	44
The ideal vector for gene therapy.....	44
Viral vectors.....	45
<i>Adenovirus vectors.....</i>	<i>46</i>
<i>Adeno-associated virus vectors.....</i>	<i>48</i>
<i>Alphavirus vectors.....</i>	<i>50</i>
<i>Baculovirus vectors</i>	<i>50</i>
<i>Foamy virus vectors</i>	<i>51</i>
<i>Herpes simplex virus vectors</i>	<i>51</i>
<i>Lentiviral vectors</i>	<i>53</i>
<i>Multicistronic retroviral vectors</i>	<i>54</i>
<i>Retroviral vectors.....</i>	<i>55</i>
<i>Oncogenic potential of retroviral vectors</i>	<i>56</i>
<i>Future prospects of viral vectors</i>	<i>57</i>
<i>Companies using viral vectors</i>	<i>57</i>
Nonviral vectors for gene therapy	59
<i>Anionic lipid-DNA complexes.....</i>	<i>59</i>
<i>Cationic lipid-DNA complexes</i>	<i>60</i>
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	<i>60</i>
<i>Electrostatic modifications of surface to improve gene delivery</i>	<i>60</i>
<i>Liposomes for gene therapy</i>	<i>61</i>

<i>Liposome-nucleic acid complexes</i>	62
<i>Liposome-HVJ complex</i>	63
<i>Transposons DNA vectors</i>	63
<i>Polycation-DNA complexes (polyplexes)</i>	64
<i>Plasmid DNA vector for treatment of chronic inflammatory disease</i>	65
<i>Polymer molecules</i>	65
<i>Synthetic peptide complexes</i>	65
<i>Future prospects of nonviral vs viral vectors</i>	65
Nanobiotechnology for gene transfer	66
<i>Nanoparticles as nonviral vectors for gene therapy</i>	66
<i>Dendrimers</i>	66
<i>Cochleates</i>	67
<i>Calcium phosphate nanoparticles as non-viral vectors</i>	67
<i>Lipid nanoparticles for nucleic acid delivery</i>	68
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	68
<i>Gelatin nanoparticles for gene delivery</i>	69
<i>Nonionic polymeric micelles for oral gene delivery</i>	69
<i>Biological nanoparticle technology</i>	69
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	69
Receptor-mediated endocytosis	70
Artificial viral vectors	71
Directed evolution of AAV to create efficient gene delivery vectors	71
Bacterial ghosts as DNA delivery systems	72
Bacteria plus nanoparticles for gene delivery into cells.....	72
Chromosome-based vectors for gene therapy	73
Companies using nonviral vectors	74
Concluding remarks about vectors	75
Cell-mediated gene therapy	76
Fibroblasts	77
Skeletal muscle cells	78
Vascular smooth muscle cells	78
Keratinocytes	78
Hepatocytes	79
Lymphocytes	79
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	79
Implantation of microencapsulated genetically modified cells	79
Stem cell gene therapy	80
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	81
<i>Improving delivery of genes to stem cells</i>	81
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	81
<i>Use of mesenchymal stem cells for gene therapy</i>	81
<i>Microporation for transfection of MSCs</i>	81
<i>In utero gene therapy using stem cells</i>	82
<i>Gene delivery to stem cells by artificial chromosome expression</i>	82
<i>Linker based sperm-mediated gene transfer technology</i>	82
<i>Combination of gene therapy with therapeutic cloning</i>	83
<i>Expansion of transduced HSCs in vivo</i>	83
<i>The future of hematopoietic stem cell gene therapy</i>	83
Routes of administration for gene therapy	83
Direct injection of naked DNA	84
Intramuscular injection	84
Intravenous DNA injection.....	85
Intraarterial delivery	85
Companies with gene delivery devices/ technologies	85
Targeted gene therapy	86
Targeted integration	87
Bacteriophage integrase system for site-specific gene delivery	87
Controlled-release delivery of DNA	87
Controlled gene therapy	88
Controlled delivery of genetic material	88
Controlled induction of gene expression	88
Drug-inducible systems for control of gene expression	89
Timed activation of gene therapy by a circuit based on signaling network	89
Small molecules for post-transcriptional regulation of gene expression	90
Engineered zinc finger DNA binding proteins for gene correction	90
Light Activated Gene Therapy	90
Spatial control of gene expression via local hyperthermia	91
Companies with regulated /targeted gene therapy	91
Gene marking	92
Germline gene therapy	92
Potential applications of human germline genome modification	92

Pros and cons of human germline genome modification	93
Role of gene transfer in antibody therapy	94
Genetically engineered vaccines	95
DNA vaccines	95
<i>DNA inoculation technology</i>	95
<i>Methods for enhancing the potency of DNA vaccines</i>	96
<i>Advantages of DNA vaccines</i>	96
Vaccine vectors	97
Challenges and limitations of genetically engineered vaccines	98
Vaccines based on reverse genetics	98
Technologies for gene suppression	98
Antisense oligonucleotides	99
Transcription factor decoys	99
Aptamers	100
Ribozymes	100
Peptide nucleic acid	100
<i>Intracellular delivery of PNAs</i>	101
Locked nucleic acid	101
<i>Zorro-LNA</i>	101
Gene silencing	102
Post-transcriptional gene silencing	102
Definitions and terminology of RNAi	102
RNAi mechanisms	102
Inhibition of gene expression by antigenic RNA	104
RNAi gene therapy	105
Application of molecular diagnostic methods in gene therapy	105
Use of PCR to study biodistribution of gene therapy vector	105
PCR for verification of the transcription of DNA	106
In situ PCR for direct quantification of gene transfer into cells	106
Detection of retroviruses by reverse transcriptase (RT)-PCR	106
Confirmation of viral vector integration	106
Monitoring of gene expression	107
<i>Monitoring of gene expression by green fluorescent protein</i>	107
<i>Monitoring in vivo gene expression by molecular imaging</i>	107
<i>Advantages of gene therapy compared with protein therapy</i>	107
3. Clinical Applications of Gene Therapy	109
Introduction	109
Bone and joint disorders	109
Bone fractures	109
Gene therapy for intervertebral disc degeneration	110
Spinal fusion	110
Osteogenesis imperfecta	111
Rheumatoid arthritis	111
<i>Local or systemic treatment</i>	112
<i>In vivo or ex vivo gene therapy of RA</i>	112
<i>Clinical trials</i>	113
Gene therapy for osteoarthritis	114
Sports injuries	115
<i>Repair of articular cartilage defects</i>	115
Regeneration and replacement of bone by gene therapy	116
Bacterial infections	117
Antisense approach to bacterial infections	117
Dentistry	117
Tissue engineering in dental implant defects	117
Endocrine disorders	118
Introduction	118
Diabetes mellitus	118
Methods of gene therapy of diabetes mellitus	118
<i>Viral vector-mediated gene transfer in diabetes</i>	119
<i>Gene delivery with ultrasonic microbubble destruction technology</i>	120
<i>Genetically engineered cells for diabetes mellitus</i>	120
<i>Genetically altered liver cells</i>	120
<i>Genetically modified stem cells</i>	121
<i>Genetically engineered dendritic cells</i>	121
<i>Insertion of gene encoding for IL-4</i>	121
<i>Concluding remarks about cell and gene therapy of diabetes</i>	121
Gene therapy of growth-hormone deficiency	122
Gene therapy of obesity	123
<i>Ad viral vector-mediated transfer of leptin gene</i>	123
<i>AAV vector-mediated delivery of GDNF for obesity</i>	124

Gastrointestinal disorders	124
Introduction	124
Methods of gene transfer to the gastrointestinal tract	125
<i>Direct delivery of genes</i>	125
<i>Naked plasmid DNA into the submucosa</i>	125
<i>Viral vectors</i>	125
<i>Receptor-mediated endocytosis</i>	125
Indications for gastrointestinal gene therapy	125
<i>Gene therapy for inflammatory disorders of the bowel</i>	126
Gene transfer to the salivary glands	127
<i>Potential clinical applications of salivary gene therapy</i>	127
Hematology	128
Hemophilias	128
<i>Gene therapy of hemophilia</i>	128
<i>Hemophilia A</i>	129
<i>Hemophilia B</i>	130
<i>Concluding remarks about gene therapy of hemophilias</i>	130
Hemoglobinopathies	131
<i>Stem cell-based gene therapy and RNAi for sickle cell disease</i>	131
<i>Gene therapy for β-thalassemia</i>	132
<i>Gene therapy of Fanconi's anemia</i>	133
Acquired hematopoietic disorders.....	134
<i>Chronic acquired anemias</i>	134
<i>Neutropenia</i>	134
<i>Thrombocytopenia</i>	135
Concluding remarks about gene therapy of hemoglobinopathies	136
Companies involved in gene therapy of hematological disorders	136
In utero gene therapy	137
Fetal gene transfer techniques.....	137
Animal models of fetal gene therapy.....	138
Potential applications of fetal gene therapy	138
<i>Fetal gene therapy for cystic fibrosis</i>	138
<i>Fetal intestinal gene therapy</i>	139
Hearing disorders	139
Potential of gene therapy	139
Vectors for gene therapy of hearing disorders.....	140
Auditory hair cell replacement and hearing improvement by gene therapy	140
Kidney diseases	141
End-stage renal disease	141
Methods of gene delivery to the kidney	141
<i>Gene transfer into kidney by adenoviral vectors</i>	142
<i>Non-viral gene transfer to the kidneys</i>	142
<i>Gene transfer into the glomerulus by HVJ-liposome</i>	142
<i>Bone marrow stem cells for renal disease</i>	142
<i>Mesangial cell therapy</i>	143
<i>Liposome-mediated gene transfer into the tubules</i>	143
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i>	144
Gene therapy in animal experimental models of renal disease	144
Genetic manipulations of the embryonic kidney	144
Antisense intervention in glomerulonephritis	145
Gene therapy for renal fibrosis.....	145
Use of genetically engineered cells for uremia due to renal failure	145
Concluding remarks.....	146
Liver disorders	146
Techniques of gene delivery to liver	147
<i>Direct injection of DNA into liver</i>	147
<i>Local gene delivery by isolated organ perfusion</i>	147
<i>Liposome-mediated direct gene transfer</i>	148
<i>Retroviral vector for gene transfer to liver</i>	148
<i>Adenoviral vectors for gene transfer to liver</i>	148
<i>Receptor-mediated approach</i>	148
Cell therapy for liver disorders	149
<i>Transplantation of genetically modified hepatocytes</i>	149
<i>Genetically modified hematopoietic stem cells</i>	149
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	149
Gene therapy of genetic diseases affecting the liver	150
<i>Crigler-Najjar syndrome</i>	150
<i>Hereditary tyrosinemia type I (HT1)</i>	150
<i>Hereditary tyrosinemia type 3</i>	150
Gene therapy of acquired diseases affecting the liver.....	151
<i>Cirrhosis of liver</i>	151

Ophthalmic disorders	151
Introduction to gene therapy of ophthalmic disorders	151
Degenerative retinal disorders	152
<i>Age-related macular degeneration</i>	152
<i>Inherited retinal degenerations</i>	154
Inherited disorders affecting vision.....	155
<i>Gene therapy for color blindness</i>	155
<i>Leber congenital amaurosis</i>	155
<i>Retinitis pigmentosa</i>	156
<i>Stargardt disease</i>	157
<i>Usher syndrome</i>	157
<i>X-linked juvenile retinoschisis</i>	157
Proliferative retinopathies	158
Methods of gene transfer to retinal cells.....	158
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	159
Prevention of complications associated with eye surgery	159
<i>Prevention of proliferative retinopathy by gene therapy</i>	159
<i>DNA nanoparticles for gene therapy of retinal degenerative disorders</i>	160
<i>Posterior capsule opacification after cataract surgery</i>	160
Autoimmune uveitis	160
Retinal ischemic injury.....	161
Corneal disorders	161
Glaucoma	162
Disorders of hearing	162
Gene therapy for hearing loss.....	162
Organ transplantation	163
Introduction	163
DNA vaccines for transplantation	163
Gene therapy for prolonging allograft survival	163
Gene therapy in lung transplantation.....	164
Role of gene therapy in liver transplantation.....	164
Gene therapy in kidney transplantation.....	164
Veto cells and transplant tolerance.....	165
Pulmonary disorders	165
Techniques of gene delivery to the lungs.....	166
<i>Adenoviral vectors</i>	166
<i>Non-viral vectors</i>	167
<i>Aerosolization as an aid to gene transfer to lungs</i>	167
Cystic fibrosis	167
<i>Genetics and clinical features</i>	167
<i>Gene therapy for CF</i>	168
<i>CFTR gene transfer in CF</i>	168
<i>Concluding remarks about gene therapy of CF</i>	169
Miscellaneous pulmonary disorders	170
<i>Gene therapy for pulmonary arterial hypertension</i>	170
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	171
<i>Pulmonary complications of α1-antitrypsin deficiency</i>	171
<i>Gene therapy for asthma</i>	172
<i>Gene therapy for adult respiratory distress syndrome</i>	173
<i>Gene therapy for lung injury</i>	173
<i>Gene therapy for bronchopulmonary dysplasia</i>	173
Concluding remarks about gene therapy of lungs	174
Companies involved in pulmonary gene therapy	174
Skin and soft tissue disorders	175
Gene transfer to the skin	175
<i>Electroporation for transdermal delivery of plasmid DNA</i>	175
<i>Electroporation for transdermal delivery of DNA vaccines</i>	175
<i>Liposomes for transdermal gene delivery</i>	176
<i>Ultrasound and topical gene therapy</i>	176
Gene therapy in skin disorders	176
<i>Gene therapy of hair loss</i>	176
<i>Gene therapy for xeroderma pigmentosa</i>	177
<i>Gene therapy for lamellar ichthyosis</i>	177
<i>Gene therapy for epidermolysis bullosa</i>	177
Gene transfer techniques for wound healing	178
Urogenital disorders	179
Gene therapy for urinary tract dysfunction	179
Gene therapy for erectile dysfunction	179
<i>NOS gene transfer for erectile dysfunction</i>	179
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	179
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	180

<i>Concluding remarks on gene therapy for erectile dysfunction</i>	180
Veterinary gene therapy	180
Gene therapy for mucopolysaccharidosis VII in dogs	181
Gene therapy to increase disease resistance.....	181
Gene therapy for infections	181
Gene therapy for chronic anemia	182
Gene therapy for endocrine disorders	182
Gene therapy for arthritis.....	182
Cancer gene therapy	183
<i>Brain tumors in cats and dogs</i>	183
<i>Breast cancer in dogs</i>	184
<i>Canine hemangiosarcoma</i>	184
<i>Canine melanoma</i>	184
<i>Canine soft tissue sarcoma</i>	185
Melanoma in horses	185
4. Gene Therapy of Genetic Disorders	187
Introduction	187
Primary immunodeficiency disorders	188
Severe combined immune deficiency	189
Chronic granulomatous disease.....	191
Wiskott-Aldrich syndrome	191
Purine nucleoside phosphorylase deficiency	192
Major histocompatibility class II deficiency	192
Future prospects of gene therapy of inherited immunodeficiencies	193
Metabolic disorders	193
Adrenoleukodystrophy	194
Canavan disease	194
Lesch-Nyhan syndrome	195
Ornithine transcarbamylase deficiency	195
Phenylketonuria	196
Porphyrias.....	196
Tetrahydrobiopterin deficiency.....	197
Lysosomal storage disorders	197
Batten disease.....	198
Fabry's disease	199
Farber's disease.....	199
Gaucher disease	199
<i>Animals models of Gaucher's disease</i>	200
<i>Gene therapy of Gaucher's disease</i>	200
Hunter syndrome	201
Combination of cell and gene therapy for Krabbe's disease.....	201
Metachromatic leukodystrophy	202
Mucopolysaccharidosis type 1 (Hurler syndrome)	202
Niemann-Pick type A disease.....	203
Pompe disease.....	203
Sanfilippo A syndrome	204
Sly syndrome	204
Tay-Sachs disease	204
Future prospects of gene therapy of lysosomal storage disorders	205
Trinucleotide repeat disorders	205
Muscular dystrophies	205
Duchenne muscular dystrophy (DMD).....	205
<i>Animal models for gene therapy of DMD</i>	206
<i>Antisense approach to DMD</i>	206
<i>Liposome-mediated gene transfer</i>	207
<i>Myoblast-based gene transfer in DMD</i>	207
<i>Plasmid-mediated gene therapy</i>	208
<i>Post-transcriptional modulation of gene expression in DMD</i>	208
<i>Repair of dystrophin gene</i>	208
<i>Routes of administration of gene therapy in DMD</i>	209
<i>Types of dystrophin constructs</i>	209
<i>Viral vectors for DMD</i>	210
<i>Conclusions and future prospects of gene therapy of DMD</i>	211
Limb-girdle muscular dystrophy	212
Myotonic dystrophy	212
Spinal muscular atrophy	212
Antisense gene therapy of SMA.....	213
Hereditary neuropathies	213
Charcot-Marie-Tooth disease	213
Hereditary axonal neuropathies of the peripheral nerves	214

Gene therapy of mitochondrial disorders	214
Companies involved in gene therapy of genetic disorders.....	215
5. Gene Therapy of Cancer	217
Strategies for cancer gene therapy	217
Direct gene delivery to the tumor	218
Injection into tumor	218
<i>Direct injection of adenoviral vectors</i>	<i>218</i>
<i>Direct injection of a plasmid DNA-liposome complex.....</i>	<i>219</i>
<i>A polymer approach to local gene therapy for cancer.....</i>	<i>219</i>
Electroporation for cancer gene therapy	219
Control of gene expression in tumor by local heat	220
Radiation-guided gene therapy of cancer	220
Nanoparticles to facilitate combination of hyperthermia and gene therapy.....	221
Cell-based cancer gene therapy	221
Adoptive cell therapy.....	221
Cytokine gene therapy.....	222
Genetic modification of human hematopoietic stem cells	225
Immunogene therapy	225
Cancer vaccines	226
Genetically modified cancer cell vaccines	226
<i>GVAX cancer vaccines.....</i>	<i>226</i>
<i>Genetically modified dendritic cells</i>	<i>227</i>
Nucleic acid-based cancer vaccines	227
<i>DNA cancer vaccines</i>	<i>228</i>
<i>RNA vaccines.....</i>	<i>228</i>
Viral vector-based cancer vaccines	228
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	<i>229</i>
Future prospects of cancer vaccines	229
Companies involved in nucleic acid-based cancer vaccines	229
Monoclonal antibody gene transfer for cancer	230
Transfer and expression of intracellular adhesion-1 molecules	231
Other gene-based techniques of immunotherapy of cancer	231
Fas (Apo-1).....	231
Chemokines	231
Major Histocompatibility Complex (MHC) Class I	232
IGF (Insulin-Like Growth Factor).....	232
Inhibition of immunosuppressive function in cancer.....	232
Delivery of toxic genes to tumor cells for eradication	233
Gene-directed enzyme prodrug therapy	233
Combination of gene therapy with radiotherapy	233
Correction of genetic defects in cancer cells	234
Targeted gene therapy for cancer	234
Bacteria as novel anticancer gene vectors	234
Cancer-specific gene expression	235
Cancer-specific transcription.....	235
Delivery of retroviral particles hitchhiking on T cells	236
Electrogene and electrochemotherapy	236
Epidermal growth factor-mediated DNA delivery	236
Gene-based targeted drug delivery to tumors.....	236
Gene expression in hypoxic tumor cells.....	237
Genetically modified T cells for targeting tumors	237
Genetically engineered stem cells for targeting tumors	238
Hematopoietic stem cells for targeted cancer gene therapy	239
Immunolipoplex for delivery of p53 gene	239
Nanomagnets for targeted cell-based cancer gene therapy.....	240
Nanoparticles for targeted site-specific delivery of anticancer genes	240
Targeted cancer therapy using a dendrimer-based synthetic vector.....	240
Tumor-targeted gene therapy by receptor-mediated endocytosis	241
Virus-mediated oncolysis	241
<i>Targeted cancer treatments based on oncolytic viruses.....</i>	<i>241</i>
<i>Oncolytic HSV.....</i>	<i>242</i>
<i>Oncolytic adenoviruses</i>	<i>242</i>
<i>Oncolytic vesicular stomatitis virus.....</i>	<i>243</i>
<i>Oncolytic paramyxovirus.....</i>	<i>244</i>
<i>Oncolytic vaccinia virus.....</i>	<i>244</i>
<i>Cancer terminator virus</i>	<i>244</i>
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	<i>245</i>
<i>Monitoring of viral-mediated oncolysis by PET.....</i>	<i>245</i>
<i>Oncolytic gene therapy</i>	<i>245</i>
<i>Companies developing oncolytic viruses.....</i>	<i>246</i>

Apoptotic approach to improve cancer gene therapy	246
Tumor suppressor gene therapy	247
P53 gene therapy.....	247
BRIT1 gene therapy	247
Nitric oxide-based cancer gene therapy	248
Nitric oxide synthase II DNA injection	248
Gene therapy for radiosensitization of cancer	248
Gene therapy of cancer of selected organs	248
Gene therapy for bladder cancer.....	248
Gene therapy for glioblastoma multiforme.....	249
<i>Targeted adenoviral vectors</i>	<i>250</i>
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	<i>251</i>
<i>Targeting normal brain cells with an AAV vector encoding interferon-β.....</i>	<i>251</i>
<i>Viral oncolysis of brain tumors</i>	<i>251</i>
<i>Autophagy induced by conditionally replicating adenoviruses</i>	<i>252</i>
<i>Oncolytic virus targeted to brain tumor stem cells.....</i>	<i>252</i>
<i>Antiangiogenic gene therapy</i>	<i>253</i>
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	<i>253</i>
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	<i>254</i>
<i>Gene therapy targeting hepatocyte growth factor.....</i>	<i>254</i>
<i>RNAi gene therapy of brain cancer</i>	<i>254</i>
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	<i>255</i>
Gene therapy for breast cancer.....	255
<i>Gene vaccine for breast cancer</i>	<i>255</i>
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	<i>256</i>
Gene Therapy for ovarian cancer	256
Gene therapy for malignant melanoma	257
Gene therapy of lung cancer.....	259
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene.....</i>	<i>259</i>
<i>Aerosol gene delivery for lung cancer</i>	<i>260</i>
Gene therapy for cancer of prostate	260
<i>Experimental studies</i>	<i>260</i>
<i>Nanoparticle-based gene therapy for prostate cancer</i>	<i>260</i>
<i>Tumor suppressor gene therapy in prostate cancer</i>	<i>261</i>
<i>Vaccines for prostate cancer.....</i>	<i>261</i>
<i>Clinical trials.....</i>	<i>261</i>
Gene therapy of head and neck cancer	262
<i>Adenoviral vector based P53 gene therapy.....</i>	<i>262</i>
Gene therapy of pancreatic cancer	262
<i>Rexin-GTM for targeted gene delivery in cancer.....</i>	<i>263</i>
<i>Targeted Expression of BikDD gene</i>	<i>263</i>
<i>Concluding remarks on gene therapy of pancreatic cancer.....</i>	<i>263</i>
Cancer gene therapy companies	264
6. Gene Therapy of Neurological Disorders	267
Indications.....	267
Gene transfer techniques for the nervous system	268
Methods of gene transfer to the nervous system	268
Ideal vector for gene therapy of neurological disorders	268
Promoters of gene transfer.....	268
Lentivirus-mediated gene transfer to the CNS.....	269
AAV vector mediated gene therapy for neurogenetic disorders.....	269
Gene transfer to the CNS using recombinant SV40-derived vectors	270
Routes of delivery of genes to the CNS	270
<i>Direct injection into CNS</i>	<i>270</i>
<i>Introduction of the genes into cerebral circulation</i>	<i>271</i>
<i>Introduction of genes into cerebrospinal fluid.....</i>	<i>271</i>
<i>Intravenous administration of vectors.....</i>	<i>271</i>
<i>Delivery of gene therapy to the peripheral nervous system</i>	<i>272</i>
Cell-mediated gene therapy of neurological disorders	272
<i>Neuronal cells.....</i>	<i>272</i>
<i>Neural stem cells and progenitor cells.....</i>	<i>272</i>
<i>Astrocytes.....</i>	<i>272</i>
<i>Cerebral endothelial cells</i>	<i>273</i>
<i>Implantation of genetically modified encapsulated cells into the brain.....</i>	<i>273</i>
Gene therapy of neurodegenerative disorders	273
Gene therapy for Parkinson disease.....	273
Rationale	274
<i>Techniques of gene therapy for PD</i>	<i>275</i>
<i>Delivery of neurotrophic factors by gene therapy</i>	<i>278</i>
<i>Delivery of parkin gene.....</i>	<i>279</i>

<i>Introduction of functional genes into the brain of patients with PD</i>	279
<i>Nanoparticle-based gene therapy for PD</i>	279
<i>Mitochondrial gene therapy for PD</i>	279
<i>RNAi approach to PD</i>	280
<i>Prospects of gene therapy for PD</i>	280
<i>Companies developing gene therapy for PD</i>	281
Gene therapy for Alzheimer disease	282
<i>Rationale</i>	282
<i>NGF gene therapy for AD</i>	282
<i>Nepriylsin gene therapy</i>	283
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	284
<i>Gene vaccination</i>	284
<i>Combination of gene therapy with other treatments for AD</i>	284
Gene therapy of Huntington disease.....	284
<i>Encapsulated genetically engineered cellular implants</i>	284
<i>Viral vector mediated administration of neurotrophic factors</i>	285
<i>RNAi gene therapy</i>	285
Gene therapy of amyotrophic lateral sclerosis	285
<i>Rationale</i>	285
<i>Technique of gene therapy of ALS</i>	285
Gene therapy of cerebrovascular diseases	287
Preclinical research in gene therapy for cerebrovascular disease	287
Animal models of stroke relevant to gene therapy	287
<i>Transgenic mice as models for stroke</i>	287
<i>Animal models for gene therapy of arteriovenous malformations</i>	288
Gene transfer to cerebral blood vessels.....	288
Gene therapy for vasospasm following subarachnoid hemorrhage	289
<i>NOS gene therapy for cerebral vasospasm</i>	290
Gene therapy for stroke.....	290
<i>Gene therapy for stroke using neurotrophic factors</i>	291
<i>Gene therapy of strokes with a genetic component</i>	292
<i>Gene therapy for intracranial aneurysms</i>	292
Concluding remarks about gene therapy for stroke.....	292
Gene therapy of injuries to the nervous system.....	293
Traumatic brain injury	293
Spinal cord injury.....	293
Gene therapy of epilepsy	294
Gene therapy for control of seizures	294
Gene therapy for neuroprotection in epilepsy.....	295
Gene therapy for genetic forms of epilepsy	296
Gene therapy for multiple sclerosis.....	296
Gene therapy for relief of pain	296
Rationale of gene therapy for pain	296
Vectors for gene therapy of pain	297
Methods of gene delivery for pain	297
<i>Endogenous analgesic production for cranial neuralgias</i>	298
<i>Gene delivery by intrathecal route</i>	298
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	299
<i>Gene therapy of peripheral neuropathic pain</i>	300
<i>Gene transfer by injections into the brain substance</i>	300
Targets for gene therapy of pain.....	300
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	300
<i>Gene therapy for producing enkephalin to block pain signals</i>	301
<i>Targeting nuclear factor-κB</i>	301
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	301
Potential applications of gene therapy for management of pain	302
Concluding remarks on gene therapy for pain	302
Gene therapy for psychiatric disorders	303
Gene therapy for depression.....	303
Gene therapy for enhancing cognition after stress	304
Companies involved in gene therapy of neurological disorders.....	304
7. Gene Therapy of Cardiovascular Disorders	305
Introduction.....	305
Techniques of gene transfer to the cardiovascular system.....	305
Direct plasmid injection into the myocardium	306
Catheter-based systems for vector delivery	306
Ultrasound microbubbles for cardiovascular gene delivery	307
Vectors for cardiovascular gene therapy.....	307
<i>Adenoviral vectors for cardiovascular diseases</i>	307
<i>Plasmid DNA-based delivery in cardiovascular disorders</i>	307

<i>Intravenous rAAV vectors for targeted delivery to the heart</i>	308
Hypoxia-regulated gene therapy for myocardial ischemia	308
Angiogenesis and gene therapy of ischemic disorders	308
Therapeutic angiogenesis vs vascular growth factor therapy	309
Gene painting for delivery of targeted gene therapy to the heart.....	309
Gene delivery to vascular endothelium	310
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	310
Vascular stents for gene delivery	310
Gene therapy for genetic cardiovascular disorders	311
Genetic disorders predisposing to atherosclerosis.....	311
Familial hypercholesterolemia (FH).....	311
Apolipoprotein E (apoE) deficiency	313
Hypertension	313
Genetic factors for myocardial infarction	314
Acquired cardiovascular diseases	314
Coronary artery disease with angina pectoris.....	314
<i>Ad5FGF-4</i>	314
Ischemic heart disease with myocardial infarction	315
<i>Myocardial repair with IGF-1 therapy</i>	316
<i>Metalloproteinase-2 inhibitor gene therapy</i>	316
Congestive heart failure	317
<i>Rationale of gene therapy in CHF</i>	317
<i>-ARKct gene therapy</i>	317
<i>Intracoronary adenovirus-mediated gene therapy for CHF</i>	318
<i>AAV-mediated gene transfer for CHF</i>	318
<i>AngioCell gene therapy for CHF</i>	318
<i>nNOS gene transfer in CHF</i>	319
Cardiomyopathies	319
Cardiac conduction disturbances	319
<i>Gene transfer approaches for biological pacemakers</i>	319
<i>Genetically engineered biological pacemakers</i>	320
Gene therapy and heart transplantation	321
Peripheral arterial disease	321
Incidence and clinical features	321
Current management	322
Gene therapy for peripheral arterial disease	322
<i>Angiogenesis by gene therapy</i>	322
<i>HIF-1α gene therapy for peripheral arterial disease</i>	322
<i>HGF gene therapy for peripheral arterial disease</i>	323
Ischemic neuropathy secondary to peripheral arterial disease.....	323
Prevention of restenosis after angioplasty	323
<i>Antisense approaches</i>	324
<i>Gene therapy to prevent restenosis after angioplasty</i>	324
<i>Techniques of gene therapy for restenosis</i>	325
<i>NOS gene therapy for restenosis</i>	326
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	327
Maintaining vascular patency after surgery.....	327
Companies involved in gene therapy of cardiovascular diseases	327
Future prospects of gene therapy of cardiovascular disorders	328

8. Gene therapy of viral infections.....	331
Introduction.....	331
Acquired Immunodeficiency Syndrome (AIDS).....	331
Current management of AIDS.....	331
Gene therapy strategies in HIV/AIDS.....	332
<i>HIV/AIDS vaccines</i>	332
<i>Insertion of protective genes into target cells</i>	333
Cell/gene therapies for HIV/AIDS	334
<i>Transplantation of genetically modified T-cells</i>	334
<i>Transplantation of genetically modified hematopoietic cells</i>	334
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	335
Inhibition of HIV-1 replication by lentiviral vectors	335
VRX496	335
Intracellular immunization.....	336
Engineered cellular proteins such as soluble CD4s	336
Intracellular antibodies	336
Anti-rev single chain antibody fragment.....	336
Use of genes to chemosensitize HIV-1 infected cells	337
Autocrine interferon (INF)- β production by somatic cell gene therapy	337
Antisense approaches to AIDS	337
<i>RNA decoys</i>	337

<i>Antisense oligodeoxynucleotides</i>	337
<i>RNA decoys</i>	338
<i>Ribozymes</i>	338
RNAi applications in HIV/AIDS	339
<i>siRNA-directed inhibition of HIV-1 infection</i>	339
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	339
<i>Bispecific siRNA constructs</i>	340
<i>Targeting CXCR4 with siRNAs</i>	340
<i>Targeting CCR5 with siRNAs</i>	340
Companies involved in developing gene therapy for HIV/AIDS	341
Conclusions regarding gene therapy of HIV/AIDS	342
Genetic vaccines for other viral infections	342
Cytomegalic virus infections	342
Viral hepatitis	343
<i>Vaccine for hepatitis B virus</i>	343
<i>Vaccine for hepatitis C virus</i>	344
Vaccine for herpes simplex virus	344
DNA vaccine against rabies	344
DNA vaccine for Ebola	345
Vaccines for avian influenza	345
<i>Future prospects of DNA vaccines for avian influenza</i>	346
<i>Human trial of a DNA vaccine for avian influenza</i>	347
Companies developing genetic vaccines for infections other than AIDS	347
9. Research, Development and Future of Gene Therapy	349
Basic research in gene therapy	349
R & D in gene therapy	349
Animal models of human diseases for gene therapy research	350
<i>Lentiviral transgenesis</i>	350
Financing research and development	350
Role of the NIH in gene therapy research	350
National Gene Vector Laboratories	350
Financing by the industry	351
Clinical trials in gene therapy	351
Clinical trials worldwide.....	351
<i>Clinical trials in cancer gene therapy</i>	352
<i>Clinical trials in cardiovascular gene therapy</i>	352
<i>Clinical trials in inherited monogenic diseases</i>	352
<i>Clinical trials for other indications</i>	352
Clinical trials in the US	353
Vectors used in gene therapy clinical trials	353
Future prospects for the gene therapy	354
How to improve gene therapy.....	355
Promising areas of application of gene therapy	355
<i>Neurological disorders</i>	356
<i>Gene therapy of cardiovascular disorders</i>	356
<i>Cancer gene therapy</i>	357
Personalized gene therapy	358
10. Regulatory, Safety and Ethical Issues of Gene Therapy	359
Regulation of gene therapy in the United States	359
US Federal guidelines for research involving recombinant DNA molecules	359
Regulation of gene therapy in US	359
Office of Biotechnology Activities.....	359
Implantation of genetically manipulated cells.....	360
Clinical trials in gene therapy.....	360
Cell and gene therapy INDs placed on hold by the FDA	360
Regulation of gene therapy in Germany	361
Preclinical research	361
Clinical Trials	361
Marketing authorization	362
Regulation of gene therapy in the United Kingdom	362
Regulation of gene therapy in France	363
Regulation of gene therapy in the Netherlands	363
Regulation of gene therapy in Australia	364
Regulation of gene therapy in Japan	365
Regulation of gene therapy in China	365
Safety issues of gene transfer	365
Adverse effects of retroviral vectors	365
<i>Insertional mutagenesis</i>	365
Adverse effects of HSV vectors	366

<i>Neurotoxicity of HSV vectors</i>	366
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	366
Adverse effects of adenoviral vectors.....	366
<i>Inflammatory effects of adenoviruses in lungs</i>	367
<i>Inflammatory effects involving the liver</i>	367
<i>Induction of immune response by adenoviral vectors</i>	367
<i>Impairment of adrenocortical steroidogenesis</i>	368
<i>Adverse effects of AAV vectors</i>	368
Toxicity associated with cationic lipid-mediated gene transfer	368
Toxicity of lipopolysaccharides	369
Potential side effects of RNAi gene therapy.....	369
Role of molecular diagnostics in safety of gene therapy	369
Quality control of vectors	370
<i>Testing for retroviruses</i>	370
<i>Adenoviral vectors</i>	370
<i>Replication competent viruses</i>	370
Genetic characteristics of viral vectors	371
Concluding remarks about safety of viral vectors	371
Ethical aspects of gene therapy	371
The lay consumer's view of somatic gene therapy ethics	372
Ethical aspects of clinical trials.....	372
Ethical aspects of germline gene therapy	373
Germline gene therapy for genetic enhancement	373
Athletic enhancement by genetic engineering	373
<i>Gene doping in sports</i>	374
<i>Gene transfer methods used for enhancing physical performance</i>	374
<i>Adverse effect of genetic engineering</i>	376
<i>Problems in detecting genetic manipulations in athletes</i>	376
<i>Ethical dilemma</i>	376
11. Markets for Gene Therapy	379
Introduction	379
Gene therapy markets in various regions of the world	379
Gene therapy markets according to therapeutic areas	380
Cancer gene therapy market	380
Markets for gene therapy of genetic disorders	380
Markets for DNA vaccines	381
DNA vaccines markets according to technologies	381
DNA vaccines markets according to therapeutic indications	381
DNA vaccines markets according to geographical areas	382
Competing treatments	382
Antisense.....	383
RNAi.....	383
Cell therapy	383
Strategies for developing gene therapy markets	383
<i>Collaboration with pharmaceutical companies</i>	384
<i>Collaboration with companies developing cell-based therapies</i>	384
<i>Overcoming obstructions to the development of gene therapy</i>	384
<i>Collaboration with academic gene therapy centers</i>	384
<i>Developing safer and cost-effective gene medicines</i>	384
Unmet needs in gene therapy	385
Promising areas for the development of gene therapy	385
12. References	387

Tables

Table 1-1: Landmarks in development of gene therapy.....	21
Table 2-1: Classification of methods of gene therapy.....	31
Table 2-2: A comparison of various physical methods of gene transfer	33
Table 2-3: Experimental applications of gene transfer by electroporation	35
Table 2-4: An overview of characteristics of commonly used viral vectors	45
Table 2-5: Companies using viral vectors.....	57
Table 2-6: Companies using nonviral vectors	75
Table 2-7: Target organs for non-viral gene therapy methods.	76
Table 2-8: Potential routes for administration of DNA	83
Table 2-9: Companies with gene delivery devices/ technologies.....	85
Table 2-10: Strategies for targeted gene therapy.....	86
Table 2-11: In vivo animal experimental studies of gene delivery with polymeric systems.....	87
Table 2-12: Approaches to controlling gene expression in gene therapy.....	88
Table 2-13: Companies with regulated / targeted gene therapy and special techniques	91

Table 2-14: Potential applications of human germline genome modification	93
Table 2-15: Applications of molecular diagnostics in gene therapy	105
Table 2-16: Advantages of gene therapy compared with protein therapy	108
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	112
Table 3-2: Gene therapy strategies for osteoarthritis.....	114
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	119
Table 3-4: Indications for gastrointestinal gene therapy	126
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	128
Table 3-6: Companies involved in gene therapy of hematological disorders	136
Table 3-7: Techniques of gene transfer to the kidneys.....	141
Table 3-8: Gene therapy in animal experimental models of renal disease.....	144
Table 3-9: Applications of gene therapy in ophthalmological disorders	152
Table 3-10: Strategies for gene delivery to the lungs	166
Table 3-11: Companies developing gene therapy for pulmonary disorders	174
Table 4-1: Genetic disorders that are being investigated for gene therapy	187
Table 4-2: X-linked immunodeficiency disorders	189
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	193
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	206
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	215
Table 5-1: Strategies for cancer gene therapy	217
Table 5-2: Cell-based gene therapy for cancer.....	221
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	229
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy.....	233
Table 5-5: Mutation compensation strategies used clinically	234
Table 5-6: Companies developing oncolytic viruses	246
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	249
Table 5-8: Clinical trials of gene therapy in ovarian cancer.....	257
Table 5-9: Gene therapy for malignant melanoma	258
Table 5-10: Clinical trials of gene therapy for prostate cancer	262
Table 5-11: Companies involved in cancer gene therapy.....	264
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	267
Table 6-2: Methods of gene transfer as applied to neurologic disorders	268
Table 6-3: Gene therapy techniques applicable to Parkinson disease	274
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	281
Table 6-5: Gene transfer in animal models of carotid artery restenosis	288
Table 6-6: Gene therapy strategies for vasospasm.....	289
Table 6-7: Neuroprotective gene therapy in animal stroke models	290
Table 6-8: Experimental gene therapy approaches for relief of pain	297
Table 6-9: Companies involved in gene therapy of neurological disorders	304
Table 7-1: Cardiovascular disorders for which gene therapy is being considered.	305
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system	306
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	328
Table 8-1: Strategies for gene therapy of AIDS	332
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	341
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	347
Table 9-1: Clinical trials of gene therapy in the US according to applications	353
Table 9-2: Potential future applications of gene therapy in disorders of the nervous system	356
Table 10-1: Genes that may be used for performance enhancement	374
Table 11-1: Gene therapy market according to regions/countries – 2009 to 2019	379
Table 11-2: Gene therapy markets according to therapeutic areas – 2009 to 2019.....	380
Table 11-3: Cancer gene therapy market according to type of cancer - 2009 to 2019.....	380
Table 11-4: Gene therapy market for selected genetic disorders - 2009 to 2019.....	381
Table 11-5: DNA vaccines markets according to technologies - 2009 to 2019.....	381
Table 11-6: DNA vaccines markets according to therapeutic indications - 2009 to 2019.....	382
Table 11-7: DNA vaccines markets according to geographical areas - 2009 to 2019	382

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	23
Figure 1-2: Relationship of DNA, RNA and protein in the cell	27
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	32
Figure 2-2: Structure of the Helios gene gun	37
Figure 2-3: Cochleate-mediated gene therapy	67
Figure 2-4: Bacteria plus nanoparticles for drug delivery into cells	72
Figure 2-5: Schematic of suppression of gene expression by RNAi	104
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	275
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	292
Figure 9-1: Product development cycle in gene therapy.....	349
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	353
Figure 9-3: Proportions of various vectors used in gene therapy trials	354
Figure 11-1: Unmet needs in gene therapy	385